Conference Reports for NATAP

Back

12th International Workshop on Clinical Pharmacology of HIV Therapy April 13-15, 2011, Miami     12th International Workshop on Clinical Pharmacology of HIV Therapy Report by Courtney Fletcher, PharmD - Courtney V. Fletcher, Pharm.D. - (04/26/11)   Food and Fat Have Little Impact on Dolutegravir, a New Integrase Inhibitor - written by Mark Mascolini - (04/18/11)   Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir - written by Mark Mascolini - (04/18/11)   Lopinavir Troughs Lower in Children on Once-Daily Dose Plus Efavirenz - written by Mark Mascolini - (04/18/11)   Lopinavir Troughs Lower in Children on Once-Daily Dose Plus Efavirenz - written by Mark Mascolini - (04/18/11)   Atazanavir Levels Indicate Need for Higher Dose During Pregnancy - written by Mark Mascolini - (04/18/11)   Four-in-One Drug Affects Levels of Oral Contraceptives Components - written by Mark Mascolini - (04/18/11)   Older Age May Slow Clearance of Once-Daily Darunavir, Which Penetrates Cells Well - written by Mark Mascolini - (04/18/11)   Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily - written by Mark Mascolini - (04/18/11)   Impact of Stomach Acid Reducers on Cobicistat and Elvitegravir - written by Mark Mascolini - (04/18/11)   Levels of Novel HIV Attachment Inhibitor With or Without Ritonavir - (04/15/11)   Half-Dose Lamivudine Not Equivalent to Full Dose in Plasma or Cells - (04/15/11)   HIV Infection Affects Cellular Pharmacology of Zidovudine and Lamivudine: 3TC for prevention - (04/15/11)   Cobicistat Has Little Impact on Key Drug-Metabolizing Enzymes - (04/14/11)   No Dolutegravir (GSK572, integrase) Dose Adjustment Needed With Efavirenz or Tipranavir/Ritonavir - (04/14/11)